Pyxis Oncology stock fell 9.82 percent on October 6 after financing
Published on 10/07/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pyxis Oncology stock (ISIN US7473241013) was last at USD 2.02 on Nasdaq on October 6, 2026, down 9.82 percent from the previous close. The move followed a financing that generated USD 110.0 million in upfront gross proceeds, according to GlobeNewswire on October 2, 2026.
Financing funds MICVO trials
The offering closed on October 1, 2026, with Pyxis Oncology issuing 36,047,919 common shares at USD 2.90 each and pre-funded warrants for 1,883,121 shares at USD 2.899. The package also included warrants for 49,310,352 shares with an exercise price of USD 3.50.
According to GlobeNewswire on October 2, 2026, full cash exercise of the milestone-linked warrants could add USD 172.6 million, taking total gross proceeds to USD 282.6 million. The proceeds are intended to advance MICVO and the planned Phase 3 Headliner trial in recurrent or metastatic head and neck cancer.
Loss widens in Q2
Pyxis Oncology's clinical progress comes with a rising cash burden. For the quarter ended June 30, 2026, the company posted a net loss of USD 25.3 million, or USD 0.40 per share, compared with a USD 18.4 million loss, or USD 0.30 per share, in the year-earlier quarter.
The USD 25.3 million loss was 37.5 percent higher than the prior-year USD 18.4 million loss. A StockTitan filing summary dated August 13, 2026, also said cash, cash equivalents, restricted cash and short-term investments totaled USD 34.5 million at June 30, 2026.
Targets remain above the market
Analyst expectations remain materially higher than the current quote. MarketBeat reported on October 4, 2026, that 10 analysts held a Moderate Buy consensus, with eight buys, one hold and one sell, and an average 12-month target of USD 8.75.
That average target lies 333.2 percent above the USD 2.02 price. MarketBeat also listed targets from USD 7 to USD 19, showing a wide range of outcomes around a clinical-stage drug developer.
PYXS remains below its yearly high
At USD 2.02 on October 6, 2026, PYXS stood 63.6 percent below its 52-week high of USD 5.55 and 96.1 percent above its 52-week low of USD 1.03. The market capitalization was USD 128.0 million and volume reached 1,404,378 shares on the same Nasdaq session.
Key facts on Pyxis Oncology stock
- Company: Pyxis Oncology, Inc.
- ISIN: US7473241013
- Ticker: PYXS
- Trading venue: Nasdaq
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 2.02
- Market capitalization: USD 128.0 million (as of October 6, 2026)
- 52-week range: USD 1.03-5.55 (as of October 6, 2026)
- Sector / Industry: Healthcare / Biotechnology
More news and analyses on Pyxis Oncology stock
